Related Experiment Video
Updated: Jul 14, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Imaging beta-amyloid burden in aging and dementia
1Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia. christopher.rowe@austin.org.au
Neurology
|May 16, 2007
Summary
[(11)C]Pittsburgh Compound B (PIB) PET imaging reveals elevated beta-amyloid (Abeta) in Alzheimer's disease and some healthy aging. Abeta may influence dementia with Lewy bodies development.
Area of Science:
- Neuroimaging
- Neurology
- Biomarkers
Background:
- Beta-amyloid (Abeta) deposition is a hallmark of Alzheimer's disease (AD).
- Quantifying Abeta burden noninvasively is crucial for understanding neurodegenerative diseases.
Purpose of the Study:
- To compare brain Abeta burden using [(11)C]Pittsburgh Compound B (PIB) Positron Emission Tomography (PET) across normal aging, AD, and other dementias.
- To investigate the relationship between Abeta deposition and cognitive status.
Main Methods:
- Studied 33 dementia patients (AD, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD]), 9 with mild cognitive impairment (MCI), and 27 healthy controls (HCs).
- Quantified Abeta burden using PIB distribution volume ratio via PET imaging.
Main Results:
- Markedly elevated cortical PIB binding in all AD patients, lower/variable in DLB, and absent in FTD.
- MCI subjects showed either an AD-like or normal PIB pattern; 22% of HCs had cortical uptake.
- PIB binding correlated with APOE-epsilon4 allele and inversely with disease onset to diagnosis interval in DLB.
Conclusions:
- PIB PET findings align with histopathological Abeta distribution in aging and dementia.
- Noninvasive longitudinal studies of Abeta deposition in preclinical AD and disease progression are now feasible.
- Abeta may influence DLB development, suggesting Abeta-reducing strategies could benefit this condition.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...